Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse.
The resistance of adult immunocompetent mice to infection with ebolaviruses has led to the development of alternative small animal models that utilise immunodeficient mice, for example the interferon α/β receptor knock-out mouse (IFNR(-/-)). IFNR(-/-) mice have been shown to be susceptible to infection with ebolaviruses by multiple routes but it is not known if this murine model is suitable for testing therapeutics that rely on the generation of an immune response for efficacy. We have tested recombinant adenovirus vectors for their ability to protect IFNR(-/-) mice from challenge with Ebola virus and have analysed the humoral response generated after immunisation. The recombinant vaccines elicited good levels of protection in the knock-out mouse and the antibody response in IFNR(-/-) mice was similar to that observed in vaccinated wild-type mice. These results indicate that the IFNR(-/-) mouse is a relevant small animal model for studying ebolavirus-specific therapeutics.
Biomedical Sciences Department, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom. Electronic address: lmobrien@dstl.gov.uk.
Lyn M
LM
O'Brien
Biomedical Sciences Department, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom.
Margaret G
MG
Stokes
Biomedical Sciences Department, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom.
Stephen G
SG
Lonsdale
Biomedical Sciences Department, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom.
David R
DR
Maslowski
Biomedical Sciences Department, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom.
Sophie J
SJ
Smither
Biomedical Sciences Department, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom.
Mark S
MS
Lever
Biomedical Sciences Department, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom.
Thomas R
TR
Laws
Biomedical Sciences Department, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom.
Stuart D
SD
Perkins
D000256:Adenoviridae / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D004195:Disease Models, Animal; D046129:Ebola Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D029043:Ebolavirus / Q000235:genetics / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors / Q000235:genetics* / Q000378:metabolism; D019142:Hemorrhagic Fever, Ebola / Q000235:genetics / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D053633:Receptor, Interferon alpha-beta / Q000172:deficiency* / Q000235:genetics; D014611:Vaccination; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D046129:Ebola Vaccines; D014759:Viral Envelope Proteins; C113189:envelope glycoprotein, Ebola virus; D053633:Receptor, Interferon alpha-beta
Ebola virus; Interferon α/β receptor knock-out mouse; Recombinant adenovirus vaccine; Small animal model